Brian Atwood is President and CEO as well as a co-founder of Cell Design Labs, a new QB3 company focused on developing the human cell engineering technology from the UCSF lab of Wendell Lim. Mr. Atwood is also a co-founder and Managing Director at Versant Ventures, a leading healthcare-focused venture capital firm, where he serves as a Managing Director. He also has more than 15 years of operating experience in the biotechnology industry. Prior to launching his career in venture capital, Mr. Atwood was Founder, President and Chief Executive Officer of Glycomed, a publicly traded biotechnology company. Mr. Atwood also currently serves as a Board member at the private companies PhaseRx, Inc., and Atreca as well as the public companies, Clovis Oncology, Inc. (CLVS), OpGen, Inc. (OPGN), and Veracyte, Inc. (VCYT).
Mr. Atwood received a BS in Biological Sciences from the University of California, Irvine, an MS in Ecology from the University of California, Davis, and an MBA from Harvard Business School.